Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Nature Biotechnology

Volumn 31, Issue 11, 2013, Pages 1023-1031

  Frampton, Garrett M ^a   Fichtenholtz, Alex ^a   Otto, Geoff A ^a   Wang, Kai ^a   Downing, Sean R ^a   He, Jie ^a   Schnall Levin, Michael ^a   White, Jared ^a   Sanford, Eric M ^a   An, Peter ^a   Sun, James ^a   Juhn, Frank ^a   Brennan, Kristina ^a   Iwanik, Kiel ^a   Maillet, Ashley ^a   Buell, Jamie ^a   White, Emily ^a   Zhao, Mandy ^a   Balasubramanian, Sohail ^a   Terzic, Selmira ^a   Richards, Tina ^a   Banning, Vera ^a   Garcia, Lazaro ^a   Mahoney, Kristen ^a   Zwirko, Zac ^a   Donahue, Amy ^a   Beltran, Himisha ^b,c   Mosquera, Juan Miguel ^b,c   Rubin, Mark A ^b,c   Dogan, Snjezana ^d   Hedvat, Cyrus V ^d   Berger, Michael F ^d   Pusztai, Lajos ^e   Lechner, Matthias ^f   Boshoff, Chris ^f   Jarosz, Mirna ^a   Vietz, Christine ^a   Parker, Alex ^a   Miller, Vincent A ^a   Ross, Jeffrey S ^a,g   Curran, John ^a   Cronin, Maureen T ^a   Stephens, Philip J ^a   Lipson, Doron ^a   Yelensky, Roman ^a   more..

^a FOUNDATION MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e YALE CANCER CENTER   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL VALIDATION; COPY-NUMBER ALTERATIONS; CURRENT DIAGNOSTICS; DIAGNOSTIC APPROACH; INSERTIONS AND DELETIONS; MASSIVELY PARALLELS; POSITIVE PREDICTIVE VALUES; VALIDATION STRATEGIES;

CELL CULTURE; DISEASES; GENE THERAPY; TESTING;

DNA SEQUENCES;

FORMALDEHYDE; GENOMIC DNA; PARAFFIN;

ARTICLE; CANCER CELL CULTURE; CANCER GENOMIC PROFILING TEST; CANCER TEST; CANCER THERAPY; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA SEQUENCE; FUSION GENE; GENE FREQUENCY; GENE INSERTION; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN GENOME; INDEL MUTATION; MAJOR CLINICAL STUDY; NEOPLASM; NUCLEIC ACID BASE SUBSTITUTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR GENE; VALIDATION STUDY;

DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; GENE FREQUENCY; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84887491073     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2696     Document Type: Article

References (53)

1. Stegmeier, F., Warmuth, M., Sellers, W.R. & Dorsch, M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin. Pharmacol. Ther. 87, 543-552 (2010).
2. Chin, L. & Gray, J.W. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008).
3. Stratton, M.R., Campbell, P.J. & Futreal, P.A. The cancer genome. Nature 458, 719-724 (2009).
4. Hudson, T.J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
5. Mardis, E.R. Genome sequencing and cancer. Curr. Opin. Genet. Dev. 22, 245-250 (2012).
6. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
7. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
8. Pao, W. New approaches to targeted therapy in lung cancer. Proc. Am. Thorac. Soc. 9, 72-73 (2012).
9. Thomas, R.K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007).
10. MacConaill, L.E. et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4, e7887 (2009).
11. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146-158 (2010).
12. Ross, J.S. Update on HER2 testing for breast and upper gastrointestinal tract cancers. Biomark. Med. 5, 307-318 (2011).
13. McCourt, C.M., Boyle, D., James, J. & Salto-Tellez, M. Immunohistochemistry in the era of personalised medicine. J. Clin. Pathol. 66, 58-61 (2013).
14. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
15. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
16. Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506-510 (2012).
17. Stephens, P.J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
18. Hammerman, P.S. et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
19. Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3, ra121 (2011).
20. Craig, D.W. et al. Genome and transcriptome sequencing in prospective refractory metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol. Cancer Ther. 12, 104-116 (2013).
21. Liang, W.S. et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS ONE 7, e43192 (2012).
22. Hadd, A.G. et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J. Mol. Diagn. 15, 234-247 (2013).
23. Kerick, M. et al. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med. Genomics 4, 68 (2011).
24. Hiatt, J.B., Pritchard, C.C., Salipante, S.J., O'Roak, B.J. & Shendure, J. Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 23, 843-854 (2013).
25. Gargis, A.S. et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol. 30, 1033-1036 (2012).
26. Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82-93 (2012).
27. Thomas, R.K. et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat. Med. 12, 852-855 (2006).
28. Beltran, H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920-926 (2013).
29. Giulino-Roth, L. et al. Targeted genomic sequencing of pediatric Burkitt lymphoma identifies recurrent alterations in anti-apoptotic and chromatin-remodeling genes. Blood 120, 5181-5184 (2012).
30. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
31. Siva, N. 1000 Genomes project. Nat. Biotechnol. 26, 256 (2008).
32. Lovly, C.M. et al. Potentially actionable kinase fusions in inflammatory myofibroblastic tumors. J. Clin. Oncol. 31, supplement, abstract 10513 (2013).
33. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
34. Albers, C.A. et al. Dindel: accurate indel calls from short-read data. Genome Res. 21, 961-973 (2011).
35. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
36. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl. Acad. Sci. USA 107, 16910-16915 (2010).
37. Yau, C. et al. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 11, R92 (2010).
38. Kim, E.S. et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011).
39. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
40. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
41. MacConaill, L.E. & Garraway, L.A. Clinical implications of the cancer genome. J. Clin. Oncol. 28, 5219-5228 (2010).
42. Swanton, C. My Cancer Genome: a unified genomics and clinical trial portal. Lancet Oncol. 13, 668-669 (2012).
43. Beadling, C. et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J. Mol. Diagn. 15, 171-176 (2013).
44. Bose, R. et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224-237 (2013).
45. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
46. Karolchik, D. et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 32, D493-D496 (2004).
47. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009).
48. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
49. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
50. Compeau, P.E., Pevzner, P.A. & Tesler, G. How to apply de Bruijn graphs to genome assembly. Nat. Biotechnol. 29, 987-991 (2011).
51. Djordjevic, B. et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod. Pathol. 25, 699-708 (2012).
52. Reis-Filho, J.S. et al. Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod. Pathol. 19, 999-1009 (2006).
53. Sherry, S.T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001).